Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

By sjmartinez • November 17, 2024

Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, Owens AT, Rader F, Nagueh SF, Olivotto I, Saberi S, Tower-Rader A, Wong TC, Coats CJ, Watkins H, Fifer MA, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn RL, Wohltman A, Maron MS; REDWOOD-HCM Investigators. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4. J Card Fail. 2024 Nov;30(11):1439-1448. doi: 10.1016/j.cardfail.2024.02.020. Epub 2024 Mar 15. PMID: 38493832.

Tags: aficamten, cardiac myosin inhibitor, Cardiology/Epi, Cedars Sinai DoM, Hypertrophic cardiomyopathy, nHCM, Publications

Bioelectronic block of stellate ganglia mitigates pacing-induced heterogeneous release of catecholamine and neuropeptide Y in the infarcted pig heart

Vrabec T, Bender S, Chan SA, Cha S, Haridas S, Hanna P, Ajijola OA, Shivkumar K, Smith C, Ardell JL. Bioelectronic block of stellate ganglia[...]

Atrial Arrhythmias After PFO Device Closure: Common, Clinically Important, and Preventable

Tobis JM, Carroll JD. Atrial Arrhythmias After PFO Device Closure: Common, Clinically Important, and Preventable? Circulation. 2024 Nov 19;150(21):1669-1670. doi: 10.1161/CIRCULATIONAHA.124.071851. Epub 2024 Nov 18.[...]

Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Abdel Jawad M, Spertus JA, Ikeaba U, Greene SJ, Fonarow GC, Chiswell K, Chan PS. Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With[...]